Pulmonx (LUNG) Expected to Post Quarterly Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) is expected to post its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $22.3940 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, April 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.33). The company had revenue of $20.59 million for the quarter, compared to analyst estimates of $20.43 million. Pulmonx had a negative return on equity of 92.94% and a negative net margin of 60.09%. On average, analysts expect Pulmonx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulmonx Stock Performance

NASDAQ LUNG opened at $1.17 on Monday. The firm’s fifty day moving average is $1.42 and its two-hundred day moving average is $1.49. Pulmonx has a one year low of $1.13 and a one year high of $3.41. The company has a debt-to-equity ratio of 0.81, a quick ratio of 4.04 and a current ratio of 4.91. The firm has a market cap of $49.42 million, a PE ratio of -0.90 and a beta of 0.30.

Institutional Investors Weigh In On Pulmonx

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cerity Partners LLC acquired a new stake in shares of Pulmonx during the 4th quarter valued at approximately $27,000. Opal Capital LLC bought a new stake in Pulmonx during the fourth quarter valued at $29,000. Lazard Asset Management LLC bought a new stake in Pulmonx during the fourth quarter valued at $31,000. Jain Global LLC acquired a new stake in shares of Pulmonx during the third quarter worth $30,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Pulmonx during the fourth quarter worth $91,000. 91.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LUNG has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research report on Monday, July 13th. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Pulmonx in a research report on Thursday, April 30th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.58.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.